Permanent Refillable Eye Implant for nAMD Shows Promise in Phase III Trial
Patients with “wet” age-related macular degeneration (nAMD) who were fitted with a permanent refillable eye implant that continuously delivers ranibizumab refilled every 6 months, achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections, according to positive topline results from the Phase III Archway study released by Genentech.
The Port Delivery System with ranibizumab (PDS) was found to be well-tolerated in the study. Full results will be presented at an upcoming medical meeting.
“For people around the world receiving frequent eye injections for neovascular AMD, this continuous delivery system could greatly reduce their treatment burden,” said Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of Global Product Development in a press release. “We look forward to presenting detailed Archway results at future medical meetings and discussing these data with regulatory authorities, with the aim of bringing this new treatment option to patients as soon as possible.”
Read the full press release here.